arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Lantern Pharma Inc.

LTRN

$2.88 ▲ +0.08 (+2.86%) at close

8 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Lantern Pharma Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $31.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -217.4% ↘

FCF / Share $-1.44 ↗

Trailing P/E —

Price / Book 5.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-17.12M

↑ +17.6% —

FCF / Share Free cash flow per share

$-1.44

↑ +13.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
EPS Growth YoY (%)	18.7% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-31.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-12.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-15.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	17.6% Good ↑ Good Improving Year-over-year change in net income	-30.2% Weak ↑ Weak Improving Year-over-year change in net income	-11.9% Weak ↑ Weak Improving Year-over-year change in net income	-15.3% Weak ↑ Weak Improving Year-over-year change in net income	-109.3% Weak Weak Year-over-year change in net income	-143.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	13.1% Fair ↑ Fair Improving Year-over-year change in free cash flow	-25.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	-12.4% Weak Weak Year-over-year change in free cash flow	-21.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
FCF / Net Income (x)	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-217.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-82.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-13.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-162.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-86.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-17.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-262.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1847%)	-98.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-754%)	-39.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-360%)	-25.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-270%)	-17.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-215%)	-30.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-300%)	-257.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1816%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-4.42M	$-7.51M	$-21.94M	$-37.20M	$-51.52M	$-19.23M	$-1.23M	$-445.16K

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Basic EPS, GAAP (USD)	$-1.57	$-1.93	$-1.47	$-1.31	$-1.13	—	—	—
Free Cash Flow per Share (USD)	$-1.44	$-1.66	$-1.32	$-1.18	$-0.97	—	—	—
Book Value per Share (USD)	$0.58	$1.96	$3.82	$5.16	$6.45	$3.17	$0.48	—
Tangible Book Value per Share (USD)	$0.58	$1.96	$3.82	$5.16	$6.45	$3.17	$0.48	—
Basic Weighted Avg Shares (shares)	10.90M	10.76M	10.84M	10.85M	10.90M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$6.30M	$20.92M	$40.66M	$55.92M	$70.39M	$19.68M	$743.53K	—
Total Equity (USD)	$6.53M	$21.19M	$40.91M	$56.04M	$71.57M	$19.70M	$943.28K	$-201.80K

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Depreciation Expense (USD)	—	—	—	$10.08K	$6.76K	$3.39K	$1.63K	—
Net Income, GAAP (USD)	$-17.12M	$-20.78M	$-15.96M	$-14.26M	$-12.36M	$-5.91M	$-2.43M	—
Operating Cash Flow (USD)	$-15.68M	$-17.81M	$-14.35M	$-12.77M	$-10.59M	$-5.65M	$-2.13M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

Lantern Pharma Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare LTRN with peers